Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BMRN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human… NCT06668805 · Noonan Syndrome Vosoritide Injection | BMRN BioMarin Pharmaceutical | Phase 2 | Terminated was active, not recruiting | 18 | Sep 16, 2026 | Registry ↗ |
| Nov 12, 2026 | Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia NCT06455059 · Hypochondroplasia Vosoritide, Placebo | BMRN BioMarin Pharmaceutical | Phase 3 | Completed was active, not recruiting | 81 | Apr 23, 2026 | Registry ↗ |
| Nov 10, 2026 | Immune Modulation During Palynziq® Treatment in Adults (IMPALA) NCT07477691 · Phenylketonuria Pegvaliase, Methotrexate | BMRN BioMarin Pharmaceutical | Phase 4 | Recruiting | 12 | Sep 30, 2027 | Registry ↗ |
| Oct 22, 2026 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondropla… NCT07441876 · Achondroplasia BMN 333, Vosoritide Injection [Voxzogo] | BMRN BioMarin Pharmaceutical | Phase 2/3 | Recruiting | 160 | Jun 2029 | Registry ↗ |
| Oct 1, 2026 | Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq NCT06780332 · Phenylketonuria, PKU RDD to Palynziq | BMRN BioMarin Pharmaceutical | Phase 4 | Completed | 9 | Aug 17, 2026 | Registry ↗ |
| Sep 9, 2026 | Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia NCT07073014 · Hypochondroplasia Vosoritide | BMRN BioMarin Pharmaceutical | Phase 3 | Enrolling by invitation | 140 | Oct 2044 | Registry ↗ |
| Jul 24, 2026 | An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participa… NCT07573631 · Duchenne Muscular Dystrophy (DMD) BMN 351 | BMRN BioMarin Pharmaceutical | Phase 2 | Enrolling by invitation | 18 | Dec 2031 | Registry ↗ |
| Jul 21, 2026 | Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketo… NCT05270837 · Phenylketonuria (PKU) Pegvaliase, Diet Only | BMRN BioMarin Pharmaceutical | Phase 3 | Active, not recruiting | 55 | Jan 14, 2025 | Registry ↗ |
| Jul 10, 2026 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active… NCT04684940 · Hemophilia A With Inhibitor, Hemophilia A With Anti Factor… Valoctocogene roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 1/2 | Completed | 10 | Apr 20, 2026 | Registry ↗ |
| Jun 30, 2026 | VIrtual STudy in Achondroplasia for the US (VISTA) NCT06168201 · Achondroplasia | BMRN BioMarin Pharmaceutical | — | Recruiting | 170 | Feb 2028 | Registry ↗ |
| Jun 30, 2026 | Cerliponase Alfa Observational Study in the US NCT04476862 · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 Cerliponase Alfa, Administration Kit | BMRN BioMarin Pharmaceutical | — | Active, not recruiting | 35 | Aug 31, 2030 | Registry ↗ |
| Jun 25, 2026 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN… NCT06280209 · Duchenne Muscular Dystrophy BMN 351 | BMRN BioMarin Pharmaceutical | Phase 1/2 | Active, not recruiting | 18 | Apr 14, 2027 | Registry ↗ |
| Jun 23, 2026 | A Study to Assess Growth in Children With Idiopathic Short Stature NCT06309979 · Idiopathic Short Stature | BMRN BioMarin Pharmaceutical | — | Recruiting | 300 | Dec 31, 2040 | Registry ↗ |
| May 22, 2026 | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature NCT06382155 · Idiopathic Short Stature Vosoritide Injection, Human Growth Hormone | BMRN BioMarin Pharmaceutical | Phase 2 | Recruiting | 100 | Jun 2026 | Registry ↗ |
| May 6, 2026 | Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants NCT06738017 · Alpha 1-Antitrypsin Deficiency BMN 349, Placebo | BMRN BioMarin Pharmaceutical | Phase 1 | Active, not recruiting | 6 | Aug 19, 2026 | Registry ↗ |
| Mar 31, 2026 | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months NCT07126262 · Hypochondroplasia Vosoritide, Placebo | BMRN BioMarin Pharmaceutical | Phase 2 | Recruiting | 60 | Jun 30, 2028 | Registry ↗ |
| Mar 25, 2026 | A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace) NCT05813678 · Phenylketonuria (PKU) Pegvaliase | BMRN BioMarin Pharmaceutical | — | Recruiting | 450 | Nov 1, 2033 | Registry ↗ |
| Mar 24, 2026 | A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for P… NCT06305234 · Phenylketonuria (PKU) Pegvaliase | BMRN BioMarin Pharmaceutical | — | Recruiting | 200 | Nov 18, 2033 | Registry ↗ |
| Mar 24, 2026 | A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq®… NCT05579548 · Phenylketonuria, Maternal Pegvaliase | BMRN BioMarin Pharmaceutical | — | Recruiting | 50 | Oct 4, 2032 | Registry ↗ |
| Mar 19, 2026 | Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A NCT06224907 · Hemophilia A Valoctocogene roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 3 | Active, not recruiting | 6 | Apr 16, 2025 | Registry ↗ |
| Mar 13, 2026 | A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia NCT04554940 · Achondroplasia vosoritide | BMRN BioMarin Pharmaceutical | Phase 2 | Active, not recruiting | 20 | Dec 2027 | Registry ↗ |
| Mar 13, 2026 | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia NCT03989947 · Achondroplasia Active BMN 111: Subcutaneous injection of recommended dose… | BMRN BioMarin Pharmaceutical | Phase 2 | Active, not recruiting | 73 | May 2038 | Registry ↗ |
| Mar 13, 2026 | An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia NCT03424018 · Achondroplasia BMN 111 | BMRN BioMarin Pharmaceutical | Phase 3 | Active, not recruiting | 119 | Jun 2031 | Registry ↗ |
| Mar 13, 2026 | A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondro… NCT02724228 · Achondroplasia BMN 111 | BMRN BioMarin Pharmaceutical | Phase 2 | Active, not recruiting | 30 | Dec 2027 | Registry ↗ |
| Jan 12, 2026 | A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMari… NCT05768386 · Hemophilia A | BMRN BioMarin Pharmaceutical | — | Enrolling by invitation | 172 | Jan 2040 | Registry ↗ |
| Oct 8, 2025 | Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids… NCT04323098 · Hemophilia A valoctocogene roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 3 | Completed | 22 | Jan 27, 2023 | Registry ↗ |
| Aug 22, 2025 | Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 NCT03520712 · Hemophilia A, Gene Therapy Valoctocogene Roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 1/2 | Terminated | 3 | Aug 7, 2024 | Registry ↗ |
| Apr 10, 2025 | Gene Therapy Study in Severe Haemophilia A Patients (270-201) NCT02576795 · Severe Haemophilia A valoctocogene roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 1/2 | Completed | 15 | Feb 14, 2024 | Registry ↗ |
| Apr 3, 2025 | A Multicenter Multinational Observational Study of Children With Hypochondroplasia NCT06212947 · Hypochondroplasia | BMRN BioMarin Pharmaceutical | — | Recruiting | 400 | Dec 31, 2043 | Registry ↗ |
| Mar 25, 2025 | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A… NCT03370913 · Hemophilia A valoctocogene roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 3 | Completed | 144 | Nov 16, 2020 | Registry ↗ |
| Feb 17, 2025 | A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With… NCT02678689 · Jansky-Bielschowsky Disease, Batten Disease BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1),… | BMRN BioMarin Pharmaceutical | Phase 2 | Completed | 14 | Apr 20, 2022 | Registry ↗ |
| Dec 12, 2024 | AAV Gene Therapy Study for Subjects with PKU NCT04480567 · Phenylketonuria (PKU) BMN 307 | BMRN BioMarin Pharmaceutical | Phase 1/2 | Active, not recruiting | 100 | Dec 2027 | Registry ↗ |
| Aug 19, 2024 | A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associ… NCT05580692 · Hemophilia A Biospecimen Collection | BMRN BioMarin Pharmaceutical | Not applicable | Terminated | 321 | Jul 31, 2024 | Registry ↗ |
| Jun 13, 2024 | A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With… NCT03583697 · Achondroplasia BMN 111, Placebo | BMRN BioMarin Pharmaceutical | Phase 2 | Completed | 75 | Jan 26, 2022 | Registry ↗ |
| Jun 11, 2024 | A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria NCT06138327 · Hyperoxaluria, Nonalcoholic Fatty Liver Disease BMN 255, Placebo | BMRN BioMarin Pharmaceutical | Phase 1 | Withdrawn | 0 | Mar 25, 2024 | Registry ↗ |
| May 16, 2024 | A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema NCT05121376 · Hereditary Angioedema, HAE Dose 1 of BMN 331, Dose 2 of BMN 331 | BMRN BioMarin Pharmaceutical | Phase 1/2 | Active, not recruiting | 44 | Nov 2028 | Registry ↗ |
| Apr 24, 2024 | A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV)… NCT04560933 · Hemophilia A Blood sample collection | BMRN BioMarin Pharmaceutical | — | Completed | 186 | Sep 20, 2023 | Registry ↗ |
| Mar 5, 2024 | A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) NCT02294877 · Mucopolysaccharidosis IV Type A, Morquio A Syndrome Vimizim® (elosulfase alfa) | BMRN BioMarin Pharmaceutical | — | Completed | 418 | Feb 21, 2024 | Registry ↗ |
| Oct 12, 2023 | Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants NCT05813314 · Achondroplasia BMN 111 administration via Injector Pen, BMN 111 administra… | BMRN BioMarin Pharmaceutical | Phase 1 | Terminated | 36 | Jun 14, 2023 | Registry ↗ |
| Oct 3, 2023 | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A… NCT03392974 · Hemophilia A Valoctocogene Roxaparvovec | BMRN BioMarin Pharmaceutical | Phase 3 | Completed | 1 | May 22, 2019 | Registry ↗ |
| Apr 24, 2023 | Kuvan®'s Effect on the Cognition of Children With Phenylketonuria NCT01965912 · Phenylketonuria Kuvan® | BMRN BioMarin Pharmaceutical | Phase 4 | Completed | 34 | Jan 4, 2023 | Registry ↗ |
| Mar 14, 2023 | A Prospective Clinical Study of Phenylketonuria (PKU) NCT04452513 · Phenylketonurias | BMRN BioMarin Pharmaceutical | — | Completed | 32 | Jun 2, 2022 | Registry ↗ |
| Jan 9, 2023 | A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD) NCT02191917 · Late-onset Pompe Disease Respiratory muscle strength measurements by different techn… | BMRN BioMarin Pharmaceutical | — | Terminated | 8 | Jun 22, 2016 | Registry ↗ |
| Oct 12, 2022 | PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry NCT00778206 · Phenylketonuria, Hyperphenylalaninaemia Kuvan | BMRN BioMarin Pharmaceutical | — | Completed | 1,887 | Jan 29, 2021 | Registry ↗ |
| Aug 24, 2022 | An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 D… NCT02485899 · Jansky-Bielschowsky Disease, Batten Disease BMN 190, Intracerebroventricular (ICV) access device | BMRN BioMarin Pharmaceutical | Phase 1/2 | Completed | 23 | Dec 10, 2020 | Registry ↗ |
| Apr 15, 2022 | Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalanine… NCT01016392 · Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or… | BMRN BioMarin Pharmaceutical | — | Completed | 627 | May 31, 2021 | Registry ↗ |
| Mar 2, 2022 | A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia NCT03197766 · Achondroplasia BMN 111, Placebo | BMRN BioMarin Pharmaceutical | Phase 3 | Completed | 121 | Oct 30, 2019 | Registry ↗ |
| Feb 17, 2022 | Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With P… NCT03694353 · Phenylketonuria (PKU) Pegvaliase | BMRN BioMarin Pharmaceutical | Phase 3 | Completed | 37 | Jan 13, 2021 | Registry ↗ |
| Oct 12, 2021 | Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) NCT00924703 · Phenylketonuria rAvPAL-PEG | BMRN BioMarin Pharmaceutical | Phase 2 | Completed | 68 | Jan 31, 2019 | Registry ↗ |
| Jul 23, 2021 | A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adul… NCT00789568 · Phenylketonuria sapropterin dihydrochloride, Moxifloxacin | BMRN BioMarin Pharmaceutical | Phase 1 | Completed | 56 | Jan 2009 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances